Why Labcorp Holdings (LH) is a Top Growth Stock for the Long-Term

Labcorp Holdings (LH) is identified as a top growth stock, earning a Zacks #2 (Buy) Rank, an 'A' VGM Score, and a 'B' Growth Style Score. The healthcare diagnostics firm is projected to achieve 11.9% year-over-year earnings growth for the current fiscal year, supported by an upward revision in one analyst's 2025 earnings estimate to $16.30 per share and an average earnings surprise of +2.5%. These strong metrics position LH as a compelling consideration for growth-focused investors.

Analysis

Labcorp Holdings (LH), a leading healthcare diagnostics and drug development company, has secured a Zacks #2 (Buy) Rank, signaling strong investment potential. The company also holds an 'A' VGM Score and a 'B' Growth Style Score, reflecting robust fundamental and growth characteristics.

LH is projected to deliver 11.9% year-over-year earnings growth for the current fiscal year, underscoring its growth trajectory. This positive outlook is further supported by an upward revision in one analyst's fiscal 2025 earnings estimate, with the Zacks Consensus Estimate now at $16.30 per share.

The company's consistent performance is highlighted by an average earnings surprise of +2.5%. These strong metrics collectively position Labcorp as a compelling candidate for growth-oriented investors seeking exposure to the healthcare sector.

Key Decisions for Investors

• Consider initiating or increasing exposure to LH given its strong Zacks #2 (Buy) Rank and 'A' VGM Score.
• Monitor future earnings reports for continued year-over-year growth, particularly the projected 11.9% for the current fiscal year, and further analyst estimate revisions.
• Evaluate LH's position within the healthcare diagnostics and drug development sector for long-term growth potential, supported by its consistent positive earnings surprises.